New transplant approach offers hope for rare immune and bone marrow diseases
NCT ID NCT04232085
First seen Jan 04, 2026 · Last updated Apr 23, 2026 · Updated 16 times
Summary
This study tests a stem cell transplant using milder chemotherapy and a drug called cyclophosphamide after transplant to help the body accept donor cells. It is for people with primary immune deficiencies, immune dysregulation, or inherited bone marrow failure. The goal is to see if donor stem cells can successfully take over and restore healthy blood and immune function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.